Elutia Celebrates First Year
Elutia Inc. (Nasdaq: ELUT) is celebrating its first anniversary since rebranding on September 6, 2023. The company, which focuses on drug-eluting biomatrix products, has achieved significant milestones in its inaugural year:
- Secured FDA approval for EluPro™, the first Antibiotic-Eluting BioEnvelope
- Successfully completed an FDA inspection of their manufacturing facility
- Implanted the first EluPro envelope on September 5, 2024
- Grew proprietary product sales by 20%
- Increased shareholder value by over 170%
The company's leadership expressed gratitude to stakeholders, partners, and employees for their contributions to Elutia's remarkable growth and accomplishments.
Elutia Inc. (Nasdaq: ELUT) celebra il suo primo anniversario dal rebranding avvenuto il 6 settembre 2023. L'azienda, specializzata in prodotti biomatrix a rilascio di farmaci, ha raggiunto traguardi significativi nel suo anno inaugurale:
- Ottenuto l'approvazione della FDA per EluPro™, il primo BioEnvelope a rilascio di antibiotici
- Completata con successo un'ispezione della FDA presso il loro stabilimento di produzione
- Impiantato il primo involucro EluPro il 5 settembre 2024
- Aumentato le vendite dei prodotti proprietari del 20%
- Incrementato il valore per gli azionisti di oltre 170%
La leadership dell'azienda ha espresso gratitudine agli stakeholder, ai partner e ai dipendenti per i loro contributi alla straordinaria crescita e ai successi di Elutia.
Elutia Inc. (Nasdaq: ELUT) está celebrando su primer aniversario desde el rebranding realizado el 6 de septiembre de 2023. La empresa, que se centra en productos biomatrix con liberación de fármacos, ha logrado hitos significativos en su primer año:
- Obtuvo la aprobación de la FDA para EluPro™, el primer BioEnvelope con liberación de antibióticos
- Completó con éxito una inspección de la FDA en su instalación de fabricación
- Se implantó el primer sobre EluPro el 5 de septiembre de 2024
- Aumentó las ventas de productos propios en un 20%
- Incrementó el valor para los accionistas en más de un 170%
El liderazgo de la empresa expresó su gratitud a las partes interesadas, socios y empleados por sus contribuciones al notable crecimiento y logros de Elutia.
Elutia Inc. (Nasdaq: ELUT)는 2023년 9월 6일 브랜딩을 전환한 지 1주년을 기념하고 있습니다. 약물 방출 바이오매트릭스 제품에 주력하는 이 회사는 첫 해에 상당한 이정표를 달성했습니다:
- EluPro™, 최초의 항생제 방출 바이오엔벨로프에 대한 FDA 승인을 획득했습니다.
- 제조 시설에 대한 FDA 검사를 성공적으로 마쳤습니다.
- 2024년 9월 5일에 첫 번째 EluPro 엔벨로프를 이식했습니다.
- 독점 제품 판매를 20% 증가시켰습니다.
- 주주 가치를 170% 이상 증가시켰습니다.
회사의 리더십은 Elutia의remarkable한 성장과 성과에 기여한 이해관계자, 파트너 및 직원들에게 감사의 뜻을 전했습니다.
Elutia Inc. (Nasdaq: ELUT) célèbre son premier anniversaire depuis le changement de marque du 6 septembre 2023. L'entreprise, qui se concentre sur des produits biomatrix à libération de médicaments, a atteint des étapes significatives au cours de sa première année :
- A obtenu l'approbation de la FDA pour EluPro™, le premier BioEnvelope à libération d'antibiotiques
- A mené avec succès une inspection de la FDA de son site de fabrication
- A implanté le premier enveloppe EluPro le 5 septembre 2024
- A augmenté les ventes de produits propriétaires de 20%
- A accru la valeur pour les actionnaires de plus de 170%
La direction de l'entreprise a exprimé sa gratitude à tous les parties prenantes, partenaires et employés pour leurs contributions à la croissance remarquable et aux succès d'Elutia.
Elutia Inc. (Nasdaq: ELUT) feiert ihr einjähriges Jubiläum seit der Umbenennung am 6. September 2023. Das Unternehmen, das sich auf medikamentenfreisetzende Biomatrixprodukte spezialisiert hat, hat im ersten Jahr erhebliche Meilensteine erreicht:
- FDA-Zulassung für EluPro™, das erste Antibiotika-freisetzende BioEnvelope, gesichert
- Erfolgreich eine FDA-Inspektion ihrer Produktionsstätte abgeschlossen
- Am 5. September 2024 das erste EluPro-Corpus implantiert
- Umsatz mit Eigenprodukten um 20% gesteigert
- Wert für Aktionäre um über 170% erhöht
Die Unternehmensführung drückte den Stakeholdern, Partnern und Mitarbeitern ihren Dank für deren Beiträge zum bemerkenswerten Wachstum und den Erfolgen von Elutia aus.
- None.
- None.
Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment
SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible. On September 6, 2023, as part of a strategic shift toward drug-eluting biologics, the company rebranded as Elutia Inc. and established the mission of “Humanizing Medicine so Patients can Thrive without Compromise.” The following day, the company began trading on Nasdaq under the new ticker symbol “ELUT.”
In its first year as Elutia, the company achieved several significant milestones and saw impressive organic growth, including:
- Focused operations on our proprietary drug-eluting biomatrix technology through the divestiture and strategic partnerships of non-core assets.
- Secured U.S. Food and Drug Administration (FDA) approval for EluPro™, the first Antibiotic-Eluting BioEnvelope.
- Successfully completed an FDA inspection of our manufacturing facility and commenced production of EluPro for commercial use.
- Implanted the first-ever EluPro antibiotic-eluting biologic envelope on September 5, 2024.
- Grew sales of our proprietary products by
20% , strengthened the balance sheet, and increased shareholder value by over170% . - Built a cohesive team of world-class professionals dedicated to our mission every day.
Kevin Rakin, Elutia’s Chairman and Co-founder, and Dr. Randy Mills Elutia’s Chief Executive Officer and Co-founder jointly commented, “It’s been an incredible year of focus and execution. While we know there is much work left to do, we want to extend our deepest thanks to everyone who made this journey possible — our shareholders, partners, physicians and care providers, and most importantly, the Elutia CRU. This remarkable team of professionals show up every day with confidence and relentless determination, all working together toward a shared goal of making a positive difference in the lives of our patients.”
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
FAQ
What major milestone did Elutia (ELUT) achieve in September 2024?
How much did Elutia's (ELUT) proprietary product sales grow in their first year?
What is EluPro and when did it receive FDA approval?
When did Elutia (ELUT) start trading on Nasdaq under its new ticker symbol?
What was the increase in shareholder value for Elutia (ELUT) in its first year?
